Table 2.
Types of pharmacotherapies used in paroxysmal and non-paroxysmal AF patients.
| Treatments/Drugs | Paroxysmal | Non-Paroxysmal | p-Value |
|---|---|---|---|
| Anticoagulant agents | 506 (65.8%) | 1188 (86.1%) | |
| Warfarin | 141 (18.3%) | 560 (40.6%) | <0.001 |
| DOAC | 365 (47.5%) | 628 (45.5%) | 0.383 |
| Antiarrhythmic medications | |||
| Beta blockers | 590 (76.7%) | 1132 (82.0%) | 0.003 |
| Amiodarone | 207 (26.9%) | 210 (15.2%) | <0.001 |
| CCB (diltiazem or verapamil) | 59 (7.7%) | 173 (12.5%) | <0.001 |
| Digoxin | 68 (8.8%) | 263 (19.1%) | <0.001 |
| Antiplatelet agents | |||
| Aspirin | 299 (38.9%) | 532 (38.6%) | 0.880 |
| Clopidogrel | 119 (15.5%) | 176 (12.8%) | 0.079 |
| Dual antiplatelets therapy | 54 (7.0%) | 87 (6.3%) | 0.512 |
| RAAS inhibitor (ACEi/ARB/Sacubitril/valsartan) | 282 (36.7%) | 549 (39.8%) | 0.156 |
| Statins | 297 (38.6%) | 513 (37.2%) | 0.507 |
| Diuretics | 217 (28.2%) | 629 (45.6%) | <0.001 |
DOAC; Direct Oral Anticoagulant, CCB; Calcium channel blocker, RAAS; Renin-angiotensin system, ACEi; Angiotensin-converting enzyme inhibitor, ARB; Angiotensin II receptor blocker.